Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma

European Journal of Cancer

Volumn 39, Issue 8, 2003, Pages 1115-1120

  Kivela T ^a   Suciu, S ^b   Hansson, J ^c   Kruit, W H J ^d   Vuoristo, M S ^e   Kloke, O ^f   Gore, M ^g   Hahka Kemppinen, M ^a   Parvinen, L M ^h   Kumpulainen, E ⁱ   Humblet, Y ^j   Pyrhonen S ^h  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b EORTC DATA CENTER   (Belgium)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d ERASMUS MC CANCER INSTITUTE   (Netherlands)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h TURKU UNIVERSITY HOSPITAL   (Finland)

ⁱ KUOPIO UNIVERSITY HOSPITAL   (Finland)

^j CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

more..

Author keywords

Bleomycin; Dacarbazine; Interferon; Lomustine; Malignant melanoma; Phase II; Staging; Uvea; Vincristine

Indexed keywords

BLEOMYCIN; DACARBAZINE; LOMUSTINE; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE;

ADULT; AGED; ALLERGY; ALOPECIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION; INFECTION; LIVER TOXICITY; LUNG TOXICITY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; UVEA MELANOMA; VOMITING;

EID: 0038402749     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00132-1     Document Type: Article

References (27)

1. Diener-West M., Earle J.D., Fine S.L.et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III. initial mortality findings. COMS report no. 18 Arch. Ophthalmol. 119:2001;969-982.
2. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II. initial mortality findings. COMS report no. 10 Am. J. Ophthalmol. 125:1998;779-796.
3. Eskelin S., Pyrhönen S., Hahka-Kemppinen M., Tuomaala S., Kivelä T. A prognostic model and staging for metastatic uveal melanoma. Cancer. 97:2003;465-475.
4. Einhorn L.H., Burgess M.A., Gottlieb J.A. Metastatic patterns of choroidal melanoma. Cancer. 34:1974;1001-1004.
5. Bedikian A.Y., Kantarjian H., Young S.E., Bodey G.P. Prognosis in metastatic choroidal melanoma. South Med. J. 74:1981;574-577.
6. Rajpal S., Moore R., Karakousis C.P. Survival in metastatic uveal melanoma. Cancer. 52:1983;334-336.
7. Gragoudas E.S., Egan K.M., Seddon J.M.et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 98:1991;383-389.
8. Dorval T., Fridman W.H., Mathiot C., Pouillart P. Interleukin-2 therapy for metastatic uveal melanoma. Eur. J. Cancer. 28A:1992;2087.
9. Kath R., Hayungs J., Bornfeld N., Sauerwein W., Hoffken K., Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer. 72:1993;2219-2223.
10. Bedikian A., Legha S.S., Mavligit G.et al. Treatment of uveal melanoma metastatic to the liver. a review of the M.D. Anderson Cancer Center experience and prognostic factors Cancer. 76:1995;1665-1670.
11. Albert D.M., Ryan L.M., Borden E.C. Metastatic ocular and cutaneous melanoma. a comparison of patient characteristics and prognosis Arch. Ophthalmol. 114:1996;108.
12. Becker J.C., Kampgen E., Brocker E. Classical chemotherapy for metastatic melanoma. Clin. Exp. Dermatol. 25:2000;503-508.
13. Mavligit G.M., Charnsangavej C., Carrasco C.H., Patt Y.Z., Benjamin R.S., Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. J. Am. Med. Assoc. 260:1988;974-976.
14. Leyvraz S., Spataro V., Bauer J.et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J. Clin. Oncol. 15:1997;2589-2595.
15. Salmon R.J., Levy C., Plancher C.et al. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur. J. Surg. Oncol. 24:1998;127-130.
16. Egerer G., Lehnert T., Max R., Naeher H., Keilholz U., Ho A.D. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma. a single-center experience with seven patients Int. J. Clin. Oncol. 6:2001;25-28.
17. Cantore M., Fiorentini G., Aitini E.et al. Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase II study. Tumori. 80:1994;37-39.
18. Nathan F.E., Berd D., Sato T.et al. BOLD+interferon in the treatment of metastatic uveal melanoma. first report of active systemic therapy J. Exp. Clin. Cancer Res. 16:1997;201-208.
19. Pyrhönen S. The treatment of metastatic uveal melanoma. Eur. J. Cancer. 34:1998;S27-S30.
20. Pyrhönen S., Hahka-Kemppinen M., Muhonen T.et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) and human leukocyte interferon for metastatic uveal melanoma. Cancer. 95:2002;2366-2372.
21. World Health Organization. Offset Publication No. 48. Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, WHO, 1979.
22. National Cancer Institute. Washington, DC, Common Toxicity Criteria Manual, Version 2.0. National Institutes of Health, National Cancer Institute, 1999, 1-27.
23. Parmar MKB, Machin D. Survival Analysis. A Practical Approach. Chichester, John Wiley & Sons, 1996.
24. Spiegel R.J., Jacobs S.L., Treuhaft M.W. Anti-interferon antibodies to interferon-alpha 2b. results of comparative assays and clinical perspective J. Interferon Res. 9(Suppl.):1989;S17-S24.
25. Myatt N., Cree I.A., Kurbacher C.M., Foss A.J., Hungerford J.L., Plowman P.N. The ex vivo chemosensitivity profile of choroidal melanoma. Anticancer Drugs. 8:1997;756-762.
26. Neale M.H., Myatt N., Cree I.A.et al. Combination chemotherapy for choroidal melanoma. ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside Br. J. Cancer. 79:1999;1487-1493.
27. Neale M.H., Myatt N.E., Khoury G.G.et al. Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Res. 11:2001;601-609.